A detailed history of Securian Asset Management, Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Securian Asset Management, Inc holds 68,858 shares of GILD stock, worth $6.34 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
68,858
Previous 71,637 3.88%
Holding current value
$6.34 Million
Previous $4.92 Million 17.42%
% of portfolio
0.17%
Previous 0.14%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$66.59 - $83.99 $185,053 - $233,408
-2,779 Reduced 3.88%
68,858 $5.77 Million
Q2 2024

Jul 15, 2024

SELL
$63.15 - $72.88 $110,575 - $127,612
-1,751 Reduced 2.39%
71,637 $4.92 Million
Q1 2024

Apr 26, 2024

SELL
$71.58 - $87.29 $392,831 - $479,047
-5,488 Reduced 6.96%
73,388 $5.38 Million
Q4 2023

Feb 08, 2024

SELL
$73.27 - $83.09 $772,192 - $875,685
-10,539 Reduced 11.79%
78,876 $6.39 Million
Q3 2023

Oct 30, 2023

SELL
$73.94 - $80.67 $1.13 Million - $1.23 Million
-15,232 Reduced 14.56%
89,415 $6.7 Million
Q2 2023

Aug 07, 2023

SELL
$76.01 - $86.7 $91,896 - $104,820
-1,209 Reduced 1.14%
104,647 $8.07 Million
Q1 2023

Apr 27, 2023

SELL
$77.31 - $88.08 $13,529 - $15,414
-175 Reduced 0.17%
105,856 $8.78 Million
Q4 2022

Feb 02, 2023

BUY
$62.32 - $89.47 $241,988 - $347,412
3,883 Added 3.8%
106,031 $9.1 Million
Q3 2022

Oct 28, 2022

BUY
$59.54 - $68.01 $26,733 - $30,536
449 Added 0.44%
102,148 $6.3 Million
Q2 2022

Aug 04, 2022

SELL
$57.72 - $65.01 $29,610 - $33,350
-513 Reduced 0.5%
101,699 $6.29 Million
Q1 2022

May 03, 2022

SELL
$57.92 - $72.58 $84,910 - $106,402
-1,466 Reduced 1.41%
102,212 $6.08 Million
Q4 2021

Feb 10, 2022

SELL
$64.88 - $73.64 $58,586 - $66,496
-903 Reduced 0.86%
103,678 $7.53 Million
Q3 2021

Nov 08, 2021

SELL
$67.69 - $73.03 $80,686 - $87,051
-1,192 Reduced 1.13%
104,581 $7.31 Million
Q2 2021

Aug 10, 2021

SELL
$63.47 - $69.35 $47,412 - $51,804
-747 Reduced 0.7%
105,773 $7.28 Million
Q1 2021

May 10, 2021

SELL
$60.0 - $68.46 $202,800 - $231,394
-3,380 Reduced 3.08%
106,520 $6.88 Million
Q4 2020

Feb 08, 2021

SELL
$56.65 - $64.55 $240,196 - $273,692
-4,240 Reduced 3.71%
109,900 $6.4 Million
Q3 2020

Nov 04, 2020

SELL
$62.1 - $78.08 $72,843 - $91,587
-1,173 Reduced 1.02%
114,140 $7.21 Million
Q2 2020

Aug 06, 2020

SELL
$72.34 - $84.0 $613,153 - $711,984
-8,476 Reduced 6.85%
115,313 $8.87 Million
Q1 2020

May 07, 2020

SELL
$62.63 - $80.22 $131,460 - $168,381
-2,099 Reduced 1.67%
123,789 $9.25 Million
Q4 2019

Feb 04, 2020

SELL
$61.62 - $67.78 $229,719 - $252,683
-3,728 Reduced 2.88%
125,888 $8.18 Million
Q3 2019

Nov 12, 2019

SELL
$62.51 - $69.0 $93,890 - $103,638
-1,502 Reduced 1.15%
129,616 $8.22 Million
Q2 2019

Aug 05, 2019

BUY
$61.87 - $69.38 $36,441 - $40,864
589 Added 0.45%
131,118 $8.86 Million
Q1 2019

Apr 26, 2019

SELL
$62.53 - $70.05 $31,202 - $34,954
-499 Reduced 0.38%
130,529 $8.49 Million
Q4 2018

Feb 04, 2019

SELL
$60.54 - $79.0 $94,805 - $123,714
-1,566 Reduced 1.18%
131,028 $8.2 Million
Q3 2018

Oct 26, 2018

SELL
$71.28 - $78.92 $24,948 - $27,622
-350 Reduced 0.26%
132,594 $10.2 Million
Q2 2018

Aug 09, 2018

SELL
$64.88 - $75.68 $26,406 - $30,801
-407 Reduced 0.31%
132,944 $9.42 Million
Q1 2018

Apr 30, 2018

BUY
$72.84 - $88.8 $72 - $88
1 Added 0.0%
133,351 $10.1 Million
Q4 2017

Feb 05, 2018

BUY
$71.15 - $83.52 $50,374 - $59,132
708 Added 0.53%
133,350 $9.55 Million
Q3 2017

Nov 03, 2017

BUY
$72.11 - $85.47 $56,606 - $67,093
785 Added 0.6%
132,642 $10.7 Million
Q2 2017

Aug 14, 2017

BUY
N/A
131,857
131,857 $9.33 Million

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $115B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Securian Asset Management, Inc Portfolio

Follow Securian Asset Management, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Securian Asset Management, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Securian Asset Management, Inc with notifications on news.